Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GGT1 | P19440 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28721112 | 1.00 | DGAT1 (0.39) | DGAT1KDM4ESMN1; SMN2HIF1AGGT1 | |
| SCHEMBL609386 | 1.00 | DGAT1 (0.39) | DGAT1KDM4ESMN1; SMN2HIF1AGGT1 | |
| SCHEMBL18817843 | 0.89 | DGAT1 (0.43) | DGAT1KDM4E | |
| SCHEMBL7705520 | 0.84 | DGAT1 (0.41) | DGAT1KDM4ESMN1; SMN2GGT1MEN1 | |
| SCHEMBL1066048 | 0.84 | DGAT1 (0.41) | DGAT1KDM4ESMN1; SMN2GGT1MEN1 | |
| SCHEMBL1422856 | 0.83 | DGAT1 (0.39) | DGAT1SMN1; SMN2HIF1AGGT1MEN1 | |
| SCHEMBL4366521 | 0.83 | DGAT1 (0.39) | DGAT1SMN1; SMN2HIF1AGGT1MEN1 | |
| SCHEMBL4366519 | 0.83 | DGAT1 (0.39) | DGAT1SMN1; SMN2HIF1AGGT1MEN1 | |
| SCHEMBL3286466 | 0.83 | DGAT1 (0.39) | DGAT1SMN1; SMN2HIF1AGGT1MEN1 | |
| SCHEMBL5498917 | 0.82 | DGAT1 (0.52) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694086-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-07-04 | — | — | US | disclosed |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-25 | — | — | US | disclosed |
| US-20160235805-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-18 | — | — | US | disclosed |
| US-9163061-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| CN-104557861-A | Hcv protease inhibitors and uses thereof | AVILA THERAPEUTICS INC | 2015-04-29 | — | — | CN | disclosed |
| CN-101951770-B | Hcv protease inhibitors and uses thereof | AVILA THERAPEUTICS INC | 2014-12-31 | — | — | CN | disclosed |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8309685-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| CN-101951770-A | Hcv protease inhibitors and uses thereof | AVILA THERAPEUTICS INC | 2011-01-19 | — | — | CN | disclosed |
| WO-2011002807-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| EP-2237667-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082697-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| CN-1130351-C | 1,5-benzodiazepine derivatives | ZERIA PHARM CO LTD (JP) | 2003-12-10 | — | — | CN | disclosed |
| CN-1246850-A | 1,5-benzodiazepine derivatives | ZERIA PHARM CO LTD (JP) | 2000-03-08 | — | — | CN | disclosed |
| US-5670479-A | α-ketoamide derivatives as inhibitors of thrombosis | CORVAS INTERNATIONAL, INC. (US) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235805-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | DGAT1 1519/4885KDM4E 2889/4885SMN1; SMN2 4140/4885 |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | DGAT1 1519/4885KDM4E 2889/4885SMN1; SMN2 4140/4885 |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | DGAT1 1519/4885KDM4E 2889/4885SMN1; SMN2 4140/4885 |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | DGAT1 1519/4885KDM4E 2889/4885SMN1; SMN2 4140/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | DGAT1 1519/4885KDM4E 2889/4885SMN1; SMN2 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.